Commercial Metals Company (NYSE:CMC) reported solid financial performance for its fiscal first quarter of 2026, ended November 30, 2025, with net earnings of $177.3 million, or $1.58 per diluted share.
China is preparing to approve the import of Nvidia Corp.’s (NASDAQ:NVDA) H200 artificial intelligence chips for select commercial customers as soon as this quarter, according to people familiar with the matter.
NervGen Pharma Corp. (NASDAQ:NGEN) officially began trading on the Nasdaq Stock Market on January 8, marking a transition into a late-stage biopharmaceutical player.
Energy Fuels (NYSE:UUUU) released an updated Feasibility Study on Thursday for its 100%-owned heavy mineral sands project in Madagascar, signaling a major step toward transforming the company into a diversified critical minerals powerhouse.
Ceragon Networks (NASDAQ:CRNT) signaled a temporary shift in its 2025 finish line, projecting fourth-quarter revenue between $81 million and $83 million.
Acuity (NYSE:AYI) reported a strong start to fiscal 2026, with first-quarter net sales climbing 20.2% to $1.1 billion.
European Union antitrust enforcers will decide by February 10 whether to approve Alphabet's (NASDAQ:GOOGL) $32 billion acquisition of cybersecurity startup Wiz.
The Competition Commission of India (CCI) told the Delhi High Court that calculating antitrust fines based on a company’s global turnover is essential to prevent multinational corporations from treating penalties as a "nominal" cost of doing business.
China will conduct a formal assessment and investigation into Meta Platforms (NASDAQ:META) acquisition of artificial intelligence startup Manus, the Chinese Ministry of Commerce (MOFCOM) announced Thursday.
Vornado Realty Trust (NYSE:VNO) has finalized the acquisition of 3 East 54th Street, a strategic Manhattan development site, for $141 million.
The deal, completed on January 7, effectively converts a distressed debt position into a fee-simple ownership of 18,400 square feet of prime Plaza District land.
Boyd Group Services (NYSE:BGSI) announced it has received all necessary regulatory clearances to finalize its acquisition of Joe Hudson’s Collision Center (JHCC), with the transaction scheduled to close on January 9, 2026.
Organon (NYSE:OGN) has entered a strategic agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid), a first-in-class treatment for high cholesterol, across France, Denmark, Iceland, Sweden, Finland, and Norway.
